Status:

COMPLETED

Pre-Workout on Exercise Performance and Cognition

Lead Sponsor:

Miami Research Associates

Collaborating Sponsors:

Glanbia Performance Nutrition

Conditions:

Healthy

Eligibility:

MALE

18-40 years

Phase:

NA

Brief Summary

The purpose of this study is to determine the effects of four different pre-workout beverages as compared to placebo on muscular strength and endurance, perceived energy and cognitive performance in h...

Eligibility Criteria

Inclusion

  • Males, aged 18 to 40 years
  • Subject has a waist circumference ≤ 97 cm.
  • Subject is a non-smoker.
  • Subject is in good health and appropriate for exercise as determined by physical examination, medical history and ECG.
  • Subject is weight training for the 6 months prior to starting the trial.
  • Subject agrees to not use any new vitamins and/or minerals until after study completion and to not take any vitamins and/or minerals 24 hours prior to the test visits.
  • Subject agrees to not use any dietary or herbal supplements until after study completion. A 7-day washout is allowed for study inclusion.
  • Subject is willing and able to comply with the protocol including:
  • Attending 5 visits each of which is approximately 4 hours long;
  • Refraining from caffeine, over-the-counter medications and alcohol for the 24 hours prior to the test visits;
  • Refraining from weight training for the 48 hours prior and refraining from any exercise other than weight training for 24 hours prior to the test visits;
  • Refraining from taking any dietary or herbal supplements throughout the study.
  • Subject is able to understand and sign the informed consent to participate in the study.

Exclusion

  • Subject has any of the following medical conditions:
  • active heart disease
  • uncontrolled high blood pressure (≥ 140/90 mmHg)
  • renal or hepatic impairment/disease
  • Type I or II diabetes
  • bipolar disorder
  • pulmonary disease (including current asthma)
  • Parkinson's disease
  • Seizure disorder
  • unstable thyroid disease
  • immune disorder (such as HIV/AIDS)
  • active psychiatric disorders (including anxiety disorders)
  • bleeding disorders
  • gastrointestinal ulcer disease
  • any medical condition deemed exclusionary by the Principal Investigator (PI)
  • Subject has any orthopedic problem(s) or history of musculoskeletal injury(ies) which make(s) resistance weight training contraindicated.
  • Subject has a history of cancer (except localized skin cancer without metastases) within 5 years prior to screening.
  • No prescription or chronic medication use allowed without PI discretion.
  • Subject is currently taking and unwilling to refrain from taking any over-the-counter stimulant medications/supplements (see section 2.6.2); seven-day washout required for study inclusion.
  • Subject is currently taking and unwilling to refrain from taking any over-the-counter allergy or asthma medication containing pseudoephedrine or ephedrine (see section 2.6.2); seven-day washout required for study inclusion.
  • Subject has an allergy to milk and phenylalanine, or any of the ingredients in the test product (see section 3.2.1).
  • Subject reports sensitivity to caffeine and/or beta-alanine.
  • Subject reports being a regular caffeine consumer defined as consuming \> 600 mg of caffeine per day.
  • Subject exhibits evidence of hepatic or renal dysfunction as evidenced by ALT, AST, AP being ≥ two times the upper limit of normal or serum creatinine value ≥ 2.0 mg/dl or other clinically significant abnormal clinical laboratory value per PI discretion.
  • Subject has a clinically relevant abnormality as defined by the PI or interpreting physician with respect to the ECG.
  • Subject has a QTcB interval \> 450 msec.
  • Subject has a history of drug or alcohol abuse in the past 12 months.
  • Subject has any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the study data.
  • Subject has taken an investigational product within 30 days of the first exercise test visit (visit 2).

Key Trial Info

Start Date :

October 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2015

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT02255201

Start Date

October 1 2014

End Date

January 1 2015

Last Update

April 7 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Miami Research Associates

Miami, Florida, United States, 33143